報價延遲最少15分鐘:2026/10/18 15:44 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
32.03 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-210.84/-3.49
|
|
企業價值
34.13M
|
| 資產負債 |
|
每股賬面淨值
-34.73
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| IRulya Therapeutics Inc is committed to transforming the lives of patients with serious, underserved diseases by developing disease-modifying therapies. The company is currently developing LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post-lung transplant (BOS), and sarcoidosis-associated pulmonary hypertension (SAPH). A Phase 2a study in PH patients has been completed; a Phase 2 clinical study in BOS patients is ongoing; a Phase 2b clinical study in PH-ILD is ongoing; and a Phase 2 clinical study in SAPH is ongoing. |
